502506-71-0

Basic information

• Product Name: (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate
• Synonyms: (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate;7-Azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylic acid, 3-broMo-, 7-(1,1-diMethylethyl) 2-ethyl ester;7-tert-Butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate
• CAS NO: 502506-71-0
• Molecular Formula: C₁₄H₁₈BrNO₄
• Molecular Weight: 344.20102
• Mol File: 502506-71-0.mol

Chemical Properties

• Boiling Point: 395.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.467±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -5.15±0.60(Predicted)
• CAS DataBase Reference: (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate(502506-71-0)
• EPA Substance Registry System: (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate(502506-71-0)

Safety Data

• Hazardous Substances Data: 502506-71-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate is used as a building block in organic synthesis for the creation of complex organic molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Drug Development:
In the pharmaceutical industry, (1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate is used as a potential lead compound for drug development. Its structural features and functional groups can be optimized to target specific biological pathways or receptors, potentially leading to the discovery of new therapeutic agents.
Used in Material Science:
(1S,4R)-7-tert-butyl 2-ethyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate is utilized in material science for the development of novel materials with unique properties. Its molecular structure and functional groups can contribute to the creation of advanced materials for applications in various industries, such as electronics, coatings, and adhesives.

Upstream product

• 5176-27-2 N-tert-butyloxycarbonyl-pyrrole 
• 623-47-2 propynoic acid ethyl ester 
• 23680-40-2 methyl 3-bromopropiolate 
• 41658-03-1 ethyl 3-bromoprop-2-ynoate 

Downstream Products

• 152533-47-6 (exo)-7-(1,1-dimethylethoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one 
• 688790-06-9 7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate 
• 1260981-47-2 7-tert-butyl 2-ethyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate 

Relevant articles and documents

BENZIMIDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

An anionic condensation and fragmentation approach to substituted 3-pyrrolines

We have identified an anionic condensation and fragmentation sequence from the coupling of 7-azabicyclo[2.2.1]heptenones with aldehydes. This reaction leads to the stereoselective formation of disubstituted 3-pyrrolines as are present in a wide array of bioactive molecules.